Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27072954 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Md M N Azim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea. Hauptthemen laut MEDLINE: Organoids, Precision Medicine, Neoplasms, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Millions of new cancer cases and deaths worldwide annually demonstrate the pressing need for predictive preclinical models that go beyond standard two-dimensional (2D) cultures and animal systems. Recent developments in three-dimensional (3D) organoid technology have yielded a powerful platform for generating patient-specific mini-organ models that faithfully recapitulate primary tumors at the genetic, phenotypic, and architectural levels. Organoids retain functional fidelity by preserving key stem cell signaling pathways, including Wnt, Notch, and Hippo, making them robust platforms for disease modeling and high-throughput drug screening. This review describes representative organoid systems, ranging from patient-derived organoids (PDOs) to induced pluripotent stem cell (iPSC)-derived organoids, that serve as disease-specific “avatars” for personalized therapeutics. Predictive accuracy rates greater than 90% have been shown in clinical studies, providing evidence for the relevance of organoids in functional precision medicine. In addition to drug discovery, the extended use of organoids in regenerative oncology can provide a unique regulatory mechanism by selectively targeting CSCs and enhancing tissue repair after cytotoxic treatments. Recent advances in organoid-on-a-chip platforms, 3D bioprinting, and artificial intelligence (AI) address critical challenges involving vascularization, immune system integration, and scalability. With the advent of standardized, GMP-compliant platforms and recent regulatory initiatives, such as the FDA Modernization Act 2.0, organoids are well-positioned to support next-generation cancer research and therapy. This review aims to bridge the gap between stem cell-derived organoids (SCDOs), providing a fully humanized platform for preclinical cancer modeling and their clinical application, and to discuss their potential to advance ethically guided, personalized cancer therapeutics with improved predictive and translational power.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
- Department of Physiology, Biochemistry, and Pharmacology, College of Veterinary Medicine, University of Kirkuk, Kirkuk 36001, Iraq.
- Department of Biotechnology & Genetic Engineering, Gopalganj Science & Technology University, Gopalganj 8100, Bangladesh.
- Department of Animal Nutrition, Genetics and Breeding, Faculty of Animal Science and Veterinary Medicine, Sher-e-Bangla Agricultural University, Dhaka 1207, Bangladesh.
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
ORCID-Profile: Md M N Azim, Kasim Sakran Abass, Atikur Rahman, Jinwon Choi, Sohyun Park, Salima Akter, Amama Rani, Bonglee Kim
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Korea Health Industry Development Institute
- Starting Growth Technological R&D Program
- Korea government
- Ministry of Health and Welfare
- Ministry of Education
Zitieren
APA
Azim, M. M. N., Bhajan, S. K., Park, J. H., Abass, K. S., Rahman, A., Choi, M., Choi, J., Park, S., Kim, H. J., Akter, S., Rani, A., & Kim, B. (2026). Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27072954
Vancouver
Azim MMN, Bhajan SK, Park JH, Abass KS, Rahman A, Choi M, et al. Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27072954
BibTeX
@article{Azim2026,
author = {Azim, Md M N and Bhajan, Sujay Kumar and Park, Jun Hong and Abass, Kasim Sakran and Rahman, Atikur and Choi, Min and Choi, Jinwon and Park, Sohyun and Kim, Hyo Jeong and Akter, Salima and Rani, Amama and Kim, Bonglee},
title = {Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27072954}
}
EUVIMED